The Price You Can Actually Buy

A quick market update

OpenAI is reportedly seeking at least $30 billion at roughly a $1.4 trillion valuation before the new money, according to Bloomberg's September 29 report. Those are fundraising discussions, not a closed round. My read: private capital is still giving the biggest names room to choose their own listing timetable.

Anthropic is moving toward the public market. Reuters reported on September 28 that its debut was likely to come after the November midterm elections, with the company targeting a valuation above $2 trillion. The timing and price remain unsettled. I'd watch the final terms before using that target to value anything else.

ElevenLabs has already reset its reference price. The company announced a completed $300 million employee tender at a $22 billion valuation on September 30, double its February Series D valuation. That's shareholder liquidity, rather than fresh primary capital. It's the confirmed event I'd use before speculating about the next round.

On Saronic, I'm hearing a potential raise at a $20 billion to $22 billion valuation. That remains unconfirmed market commentary; the company-announced reference is March's $1.75 billion Series D at $9.25 billion. With the September Navy production award and Port Alpha construction underway, I'd want to see how the proposed price lines up with deliveries, cash needs, and future dilution.

Shield AI is reportedly in talks for another raise at a valuation of at least $20 billion. Its March financing announcement put Series G equity at a $12.7 billion post-money valuation and included a separate preferred-equity financing. I'd keep the reported next-round target separate from the announced financing and compare the rights before comparing prices.

These updates give us new numbers to work with. They also make the actual transaction worth a closer look.

What the quote buys you

A 10% discount can get a lot less interesting once you read the documents.

The company might be right. The price might look right. Then you add the entry fee, the carry, and the time before you can actually sell.

The last few editions looked at valuations moving faster than the last round could keep up. This issue, I want to look at what those quoted valuations actually buy you.

I'd want the ownership and the economics on the same page before calling anything cheap.

A mark is a starting point

Forge's pricing explainer, updated this month, describes how its company price is calculated. It combines completed secondary transactions, funding-round information, and indications of interest. It's an indicative price, and it can differ from the last completed trade.

That's useful information. A seller still has to agree to your size, and the transaction still has to clear.

When someone quotes a price, I'd ask what produced it and when. A completed block last week tells me something different from an asking price that has been sitting there for a month.

Put the fees in dollars

Take a simple hypothetical. You buy $100,000 of underlying shares, pay a 6% entry fee on top, and owe 10% carry on the profit from those shares.

The shares double. A good result.

Your total cash outlay was $106,000. The shares produce $200,000 at exit. Carry takes $10,000, leaving you $190,000. Your return on the cash you put in is 79.2%, before any other expenses or taxes.

Same 2x outcome. Different return.

Both cases assume $106,000 paid in and $190,000 distributed at exit, with no interim distributions. The 2x outcome refers to the underlying shares; the investor receives 1.79x total cash invested. Hypothetical, before other expenses and taxes.

The business delivered the same outcome. The extra 2 years changed the investment.

That doesn't make a fee-bearing deal unattractive. It makes the actual terms worth calculating before the company name does all the selling. Different carry bases, hurdles, and expenses will change this example.

Ownership needs its own answer

OpenAI's published policy requires written consent for direct or indirect equity transfers. It also warns about unauthorized SPV interests, tokens, and forward contracts marketed as exposure to its equity.

For any proposed transaction, I'd want to know which entity holds the shares, which entity I'm investing in, and what approvals apply. I'd also want to know who decides when the position gets sold and when proceeds get distributed.

A direct share purchase and an interest in a vehicle can both be worth evaluating. The documents determine whether the economics and control fit the price.

The names worth a closer look

Stripe is still a useful case study. Its February announcement set an employee tender at a $159 billion valuation. That gives us a dated, company-announced liquidity event to work from. It doesn't promise that a later buyer can enter the next tender or sell on the same terms.

Anthropic announced its $65 billion Series H at a $965 billion post-money valuation in May. That's a financing reference. Before comparing secondary paper with it, I'd want to understand the security being offered and its rights. A similar implied valuation doesn't answer that question.

Saronic adds something different to the list. On September 29, the company announced a Navy production award for its Marauder autonomous ship. The next day, it announced the start of construction at Port Alpha in Brownsville, describing a project requiring more than $3 billion in private capital investment.

My question there would be about production and funding. How does the order book turn into deliveries and cash, and how much more capital gets raised along the way? Those answers matter to what today's buyer eventually owns. The shipyard budget is a company-announced plan, not revenue.

Polymarket offers another distinction worth keeping straight. ICE announced a $600 million direct investment in March and said it expected to buy up to $40 million of securities from existing holders. Money going into the company and money going to selling shareholders serve different purposes. I'd want that split clear in any financing used to justify a secondary price.

What I'd put in front of an investment committee

The share class and ownership chain. Total cash required at entry. Every fee layer and the carry calculation. The approvals needed to close. A return case that still works if liquidity arrives 2 years later than expected.

I'd also include what happens if the next round never arrives at the valuation being discussed. A proposed financing can help frame a scenario. I wouldn't use it to make today's entry look cheaper than it is.

That is the next step in the stale-mark discussion. Once the valuation reference is current, you still have to decide whether the actual investment works.

For readers comparing secondary opportunities right now, where are you seeing the biggest difference between the headline quote and the final economics?

If you're comparing secondary opportunities and want to compare notes, reach out at info@theprincecg.com.

Prince Capital is a family office private investment firm. Views expressed are the author's own and include market commentary that has not been independently confirmed. Prince Capital may hold or arrange positions in companies discussed. This material is for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security. The fee example is hypothetical and is not a statement of available terms or expected returns.